Evidence map›Paper›PMID 36077871›Full record

ArticleCancers2022

A Score to Predict the Malignancy of a Breast Lesion Based on Different Contrast Enhancement Patterns in Contrast-Enhanced Spectral Mammography.

Luca Nicosia, Anna Carla Bozzini, Simone Palma, Marta Montesano, Filippo Pesapane, Federica Ferrari, Valeria Dominelli, Anna Rotili, Lorenza Meneghetti, Samuele Frassoni and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. State-of-the-art for contrast-enhanced mammography.The British journal of radiology · 2024
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Luca NicosiaBreast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0003-3979-8075
Anna Carla BozziniBreast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Simone PalmaUniversity Department of Radiological and Hematological Sciences, Catholic University of the Sacred Heart, Largo Francesco Vito 1, 00168 Rome, Italy.
Marta MontesanoBreast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Filippo PesapaneBreast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Federica FerrariBreast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Valeria DominelliBreast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Anna RotiliBreast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Lorenza MeneghettiBreast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Samuele FrassoniDepartment of Statistics and Quantitative Methods, University of Milan-Bicocca, 20126 Milan, Italy.ORCID 0000-0002-4265-2627
Vincenzo BagnardiDepartment of Statistics and Quantitative Methods, University of Milan-Bicocca, 20126 Milan, Italy.
Claudia SangalliData Management, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Enrico CassanoBreast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-3437-8939
European Institute of Oncology · ITUniversity of Milano-Bicocca · ITData Management (Italy) · ITUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To create a predictive score of malignancy of a breast lesion based on the main contrast enhancement features ascertained by contrast-enhanced spectral mammography (CESM). Methods: In this single-centre prospective study, patients with suspicious breast lesions (BIRADS > 3) were enrolled between January 2013 and February 2022. All participants underwent CESM prior to breast biopsy, and eventually surgery. A radiologist with 20 years’ experience in breast imaging evaluated the presence or absence of enhancement and the following enhancement descriptors: intensity, pattern, margin, and ground glass. A score of 0 or 1 was given for each descriptor, depending on whether the enhancement characteristic was predictive of benignity or malignancy (both in situ and invasive). Then, an overall enhancement score ranging from 0 to 4 was obtained. The histological results were considered the gold standard in the evaluation of the relationship between enhancement patterns and malignancy. Results: A total of 321 women (median age: 51 years; range: 22−83) with 377 suspicious breast lesions were evaluated. Two hundred forty-nine lesions (66%) have malignant histological results (217 invasive and 32 in situ). Considering an overall enhancement score ≥ 2 as predictive of malignancy, we obtain an overall sensitivity of 92.4%; specificity of 89.8%; positive predictive value of 94.7%; and negative predictive value of 85.8%. Conclusions: Our proposed predictive score on the enhancement descriptors of CESM to predict the malignancy of a breast lesion shows excellent results and can help in early breast cancer diagnosis and in avoiding unnecessary biopsies.

Indexed as

biopsybreastbreast carcinomacontrast-enhanced spectral mammography (CESM)score

Identifiers

PMID36077871
PMCPMC9455061
OpenAlexW4294862145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.